X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Zoryve-Generic (roflumilast), PDE4 Inhibitor, small molecule. It is a topical cream indicated for the treatment of plaque psoriasis in patients six years of age and older.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sol-Gel Technologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
The net proceeds will be used in the development and commercialization of Zoryve (roflumilast), which is a phosphodiesterase 4 inhibitor. It is being evaluated in clinical trial studies for the treatment of Atopic dermatitis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 04, 2024
Details:
The net proceeds will be used in the development and commercialization of Zoryve (roflumilast), which is a phosphodiesterase 4 inhibitor. It is being evaluated in clinical trial studies for the treatment of Atopic dermatitis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 28, 2024
Details:
The collaboration aims to enable Sato to concentrate on the development, manufacturing, and commercialization of topical Zoryve (roflumilast) in Japan. It is used in the treatment of Plaque Psoriasis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sato Yakuhin Kogyo Co., Ltd
Deal Size: $40.0 million Upfront Cash: $25.0 million
Deal Type: Collaboration February 28, 2024
Details:
Zoryve (roflumilast) is a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. Its topical foam (0.3%) is approved for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
Zoryve (roflumilast) is a once-daily, PDE4 inhibitor steroid-free cream which is being investigated in phase 3 clinical trials for adults and children 6 years of age and older with atopic dermatitis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2024
Details:
Zoryve (roflumilast) is a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. Its topical foam (0.3%) is approved for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
Zoryve (roflumilast) topical foam, 0.3%, is indicated for treatment of seborrheic dermatitis in adult & pediatric patients 9 years of age & older. Zoryve, roflumilast cream 0.3%, is approved by FDA for the treatment of plaque psoriasis in individuals 6 years of age and older.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
Zoryve (roflumilast) is a PDE4 Inhibitor small molecule drug, formulated as a topical cream for the treatment of Atopic Dermatitis in Adults and Children Down to Age 6.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
Zoryve® (roflumilast cream) is a once-daily steroid free topical phosphodiesterase-4 (PDE4) inhibitor, which is used for topical treatment of Psoriasis in Children Ages 6 to 11.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
Arcutis intends to use the net proceeds to fund the continued development, approval and commercialization of its multiple programs, including for its potential launches in seborrheic dermatitis and atopic dermatitis and further patient expansion within psoriasis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-154
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 19, 2023
Details:
Zoryve® (roflumilast cream) is a once-daily steroid free topical phosphodiesterase-4 (PDE4) inhibitor, which is used for topical treatment of Psoriasis in Children Ages 6 to 11.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2023
Details:
Zoryve® (roflumilast cream 0.3%) is a once-daily steroid free topical phosphodiesterase-4 (PDE4) inhibitor, which is investigated for topical treatment of mild to moderate atopic dermatitis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
Zoryve® (roflumilast cream 0.3%) is a once-daily steroid free topical phosphodiesterase-4 (PDE4) inhibitor, which is investigated for topical treatment of mild to moderate atopic dermatitis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
Zoryve® (roflumilast cream 0.3%) is a once-daily steroid free topical phosphodiesterase-4 (PDE4) inhibitor, which is investigated for topical treatment of mild to moderate atopic dermatitis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
Under the collaboration, Huadong will receive license for both the cream and foam formulations of topical Zoryve (roflumilast), a next generation PDE4 inhibitor, for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, and atopic dermatitis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Huadong Medicine
Deal Size: $94.2 million Upfront Cash: $30.0 million
Deal Type: Collaboration August 10, 2023
Details:
ARQ-154 (roflumilast) is a once-daily, steroid-free PDE4 inhibitor cream, provides rapid results for both hard-to-treat areas, such as knees and elbows, and sensitive areas such as the face, intertriginous areas, and genitalia in pediatric patients with 2-5 children.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-154
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
Zoryve® (roflumilast cream) is a once-daily steroid free topical phosphodiesterase-4 (PDE4) inhibitor, which is used for topical treatment of Plaque Psoriasis in Individuals 12 Years and Older.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2023
Details:
Roflumilast and its active metabolite (roflumilast N-oxide) are selective inhibitors of phosphodiesterase 4 (PDE4), which reduces inflammation in the lungs that leads to chronic obstructive pulmonary disease (COPD).
Lead Product(s): Roflumilast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Daliresp-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2023
Details:
Zoryve (roflumilast), a once-daily, steroid-free PDE4 inhibitor cream, it is being developed for the treatment of seborrheic dermatitis in individuals aged 9 years and older.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
ZORYVE (roflumilast), a once-daily, steroid-free PDE4 inhibitor cream, provides rapid results for both hard-to-treat areas, such as knees and elbows, and sensitive areas such as the face, intertriginous areas, and genitalia.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
Arcutis is developing topical cream and foam formulations of ARQ-154 (roflumilast), a highly potent and selective PDE4 inhibitor being investigated as a once-daily, nonsteroidal, topical treatment for multiple dermatologic conditions.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-154
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
Zoryve® (roflumilast cream 0.3%) is a once-daily steroid free topical phosphodiesterase-4 (PDE4) inhibitor, indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2023
Details:
ZORYVE (roflumilast) cream 0.3% is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
ZORYVE (roflumilast) cream 0.3% is a next generation topical inhibitor of phosphodiesterase-4 (PDE4) and the first topical PDE4 inhibitor to be approved by the FDA for adults and adolescents with plaque psoriasis, including intertriginous psoriasis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
Zoryve (roflumilast) cream is next generation topical PDE4 inhibitor. PDE4 – an established target in dermatology has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and COPD.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2022
Details:
ZORYVE (roflumilast) cream 0.3% is a next generation topical inhibitor of phosphodiesterase-4 (PDE4) and the first topical PDE4 inhibitor to be approved by the FDA for adults and adolescents with plaque psoriasis, including intertriginous psoriasis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
Study met its primary endpoint with 80% of individuals treated with ARQ-154 (roflumilast) foam achieving Investigator Global Assessment (IGA) Success compared to 59% of patients treated with vehicle (P<0.0001).
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-154
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
ZORYVE (roflumilast) cream 0.3% is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zorvye
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
Zorvye (roflumilast) cream is a next generation topical PDE4 inhibitor. PDE4 – an established target in dermatology – is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zorvye
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
Details:
As the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved for the treatment of plaque psoriasis, ZORYVE (roflumilast) clears plaques and reduces itch rapidly in all affected areas of the body, including intertriginous areas (areas of skin-to-skin contact).
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
ZORYVE (roflumilast) cream 0.3%,is a selective inhibitor of phosphodiesterase-4 (PDE-4) for treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: Zoryve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
ARQ-151 (roflumilast) met its primary endpoint and had an Investigator Global Assessment (IGA) success rate of 42.4% compared to a vehicle rate of 6.1% (P<0.0001), and 37.5% compared to a vehicle rate of 6.9% (P<0.0001), in DERMIS-1 and DERMIS-2.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-151
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2022
Details:
Study met its primary endpoint with 80.1% of individuals treated with ARQ-154 (roflumilast) foam achieving Investigator Global Assessment (IGA) Success compared to 59.2% of patients treated with vehicle (P<0.0001).
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-154
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Roflumilast foam is a once-daily, topical formulation of a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor, designed to treat all areas of the body, including the face and particularly hair-bearing areas such as the scalp.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-154
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2022
Details:
Pooled analysis of DERMIS-1 and DERMIS-2 demonstrated significantly more roflumilast-treated patients achieved Investigator Global Assessment (IGA) success (40%) at week 8 compared to vehicle (7%), consistent with results from the individual studies.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-151
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2022
Details:
Phase 2 study’s primary endpoint assessed at week 8, roflumilast foam, a highly potent and selective PDE4 inhibitor, 0.3% achieved an IGA success rate of 73.8% compared to a vehicle rate of 40.9% (p<0.0001) for Seborrheic dermatitis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-154
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2022
Details:
Roflumilast tablets are indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
Lead Product(s): Roflumilast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Roflumilast-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022
Details:
This additional capital further strengthens Arcutis’ balance sheet in advance of a potential 2022 Food and Drug Administration (FDA) approval and launch of topical roflumilast cream in plaque psoriasis, and in advance of three 2022 pivotal clinical data readouts.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-151
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SLR Capital Partners
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing December 23, 2021
Details:
NDA supported by positive efficacy data of ARQ-151 (Roflumilast) from the pivotal Phase 3 DERMIS 1 and DERMIS 2 clinical studies, as well as results from the long-term safety study.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-151
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2021
Details:
Roflumilast Cream is a topical cream formulation of a highly potent and selective PDE4 inhibitor for the treatment of mild-to-severe plaque psoriasis. Roflumilast has been approved by U.S. FDA for chronic obstructive pulmonary disease.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-151
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
Details:
Once-daily roflumilast cream reduced both the severity and burden of itch, and improved quality of life, in the DERMIS-1 and DERMIS-2 Phase 3 pivotal studies in chronic plaque psoriasis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-151
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
Roflumilast foam is a once-daily topical foam formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 (PDE4) inhibitor, which the Company is developing for both seborrheic dermatitis and scalp and body psoriasis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-154
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2021
Details:
Presentation will highlight efficacy and safety data from the DERMIS-1 and DERMIS-2 pivotal Phase 3 studies evaluating roflumilast cream (ARQ-151) as a potential topical once-daily treatment for chronic plaque psoriasis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-151
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2021
Details:
New findings from the late-breaking presentation demonstrate that roflumilast foam significantly improved both scalp and body psoriasis, with improvement as early as two weeks after treatment initiation.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-151
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
Details:
Presentations will highlight new data on the safety, efficacy, and tolerability of topical roflumilast cream for the treatment of chronic, mild-to-severe plaque psoriasis as well as once-daily, topical roflumilast foam for scalp and body psoriasis and seborrheic dermatitis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-151
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2021
Details:
Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 inhibitor (PDE4), which the Company is developing for plaque psoriasis and AD.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-151
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
Details:
Poster presentations highlight new data for roflumilast cream, including long-term safety and efficacy results in adults with chronic plaque psoriasis.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-151
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2021
Details:
In DERMIS-1 and DERMIS-2, roflumilast cream was generally safe and well-tolerated. The incidence of Treatment Emergent Adverse Events (TEAEs) was low and similar between active treatment and vehicle, with most TEAEs assessed as mild to moderate in severity.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-151
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2021
Details:
Phase 3 development to consist of single pivotal trial. Roflumilast foam potential “Best in Class” topical PDE4 inhibitor. Prior studies show that roflumilast foam provided statistically significant improvement and a favorable safety and tolerability profile.
Lead Product(s): Roflumilast
Therapeutic Area: Dermatology Product Name: ARQ-154
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
